Matisse Capital Procept Bio Robotics Corp Transaction History
Matisse Capital
- $205 Million
- Q3 2024
A detailed history of Matisse Capital transactions in Procept Bio Robotics Corp stock. As of the latest transaction made, Matisse Capital holds 10,468 shares of PRCT stock, worth $849,687. This represents 0.41% of its overall portfolio holdings.
Number of Shares
10,468Holding current value
$849,687% of portfolio
0.41%Shares
1 transactions
Others Institutions Holding PRCT
# of Institutions
266Shares Held
38MCall Options Held
262KPut Options Held
257K-
Vanguard Group Inc Valley Forge, PA4.84MShares$393 Million0.01% of portfolio
-
Black Rock Inc. New York, NY3.49MShares$283 Million0.0% of portfolio
-
Alliancebernstein L.P. New York, NY1.53MShares$125 Million0.04% of portfolio
-
Loomis Sayles & CO L P1.24MShares$101 Million0.13% of portfolio
-
State Street Corp Boston, MA1.18MShares$95.7 Million0.0% of portfolio
About PROCEPT BioRobotics Corp
- Ticker PRCT
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Devices
- Shares Outstandng 44,592,300
- Market Cap $3.62B
- Description
- PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aqu...